Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cindunistat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 6/20 | 0.51 |
| ▸ | NOS2 | P35228 | 6/20 | 0.51 |
| ▸ | NOS3 | P29474 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GGT1 | P19440 | 1/20 | 0.35 |
| ▸ | ARG1 | P05089 | 1/20 | 0.33 |
| ▸ | ARG2 | P78540 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cindunistat SCHEMBL5640418 | 1.00 | NOS1 (0.51) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL27623381 | 1.00 | NOS1 (0.51) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL5644203 | 0.98 | NOS1 (0.49) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL14572932 | 0.98 | NOS1 (0.49) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL119959 | 0.98 | NOS1 (0.49) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL29379550 | 0.93 | NOS1 (0.46) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL1841632 | 0.93 | NOS1 (0.46) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL27623377 | 0.93 | NOS1 (0.46) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL6313297 | 0.91 | NOS1 (0.43) | NOS1NOS2NOS3TSHRGGT1 | |
| Cindunistat SCHEMBL1842090 | 0.91 | NOS1 (0.43) | NOS1NOS2NOS3TSHRGGT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995281-B2 | Methods for selectively removing counterions from compounds and compounds derived from such methods | PFIZER, INC. (US) | 2006-02-07 | — | — | US | claimed |
| EP-1603671-A2 | METHODS FOR SELECTIVELY REMOVING COUNTERIONS FROM COMPOUNDS AND COMPOUNDS DERIVED FROM SUCH METHODS | Pharmacia Corporation (US) | 2005-12-14 | — | — | EP | claimed |
| US-20040225150-A1 | Methods for selectively removing counterions from compounds and compounds derived from such methods | PHARMACIA & UPJOHN COMPANY | 2004-11-11 | — | — | US | claimed |
| WO-2004081073-A2 | METHODS FOR SELECTIVELY REMOVING COUNTERIONS FROM COMPOUNDS AND COMPOUNDS DERIVED FROM SUCH METHODS | PHARMACIA CORPORATION (US) | 2004-09-23 | — | — | WO | claimed |
| EP-1603872-B1 | S-[2-[(1-IMINOETHYL)AMINO]ETHYL]-2-METHYL-L-CYSTEINE MALEATE HYDROCHLORIDE CRYSTALLINE SALT | PHARMACIA CORP (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7767850-B2 | S-[2-[(1-iminoethy)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride crystalline salt | PFIZER INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090215891-A1 | S-[2-[(1-lminoethy)Amino]Ethyl]-2-Methyl-L-Cysteine Maleate Hydrochloride Crystalline Salt | PFIZER, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-7196118-B2 | Amidino compounds useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1575563-B1 | NON-HYGROSCOPIC FORMULATION COMPRISING A HYDROSCOPIC DRUG | PHARMACIA CORP (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7102013-B2 | Methods of making amidino compounds useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION (US) | 2006-09-05 | — | — | US | disclosed |
| US-7012098-B2 | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers | PHARMACIA CORPORATION (US) | 2006-03-14 | — | — | US | disclosed |
| US-6995281-B2 | Methods for selectively removing counterions from compounds and compounds derived from such methods | PFIZER, INC. (US) | 2006-02-07 | — | — | US | disclosed |
| US-20030013702-A1 | Agents and methods for treatment of cancer | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | disclosed |
| EP-1265860-A1 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1265859-A2 | AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | Pharmacia Corporation (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20020111493-A1 | Amidino compounds useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-08-15 | — | — | US | disclosed |
| US-6403830-B2 | A S-(2-(1-IMINOETHYL)AMINO)ETHYL)-2-METHYL-L-CYSTEINE AND SALTS | PHARMACIA CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020019563-A1 | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors | PHARMACIA LLC | 2002-02-14 | — | — | US | disclosed |
| WO-2001072702-A2 | AMIDINO COMPOUNDS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001072703-A1 | AMIDINO COMPOUND AND SALTS THEREOF USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | PHARMACIA CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013702-A1 | Agents and methods for treatment of cancer | FAP, APC, PTGIS | NOS1 20/4885NOS2 11/4885NOS3 22/4885 |
| US-20020111493-A1 | Amidino compounds useful as nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | NOS1 2/4885NOS2 1/4885NOS3 3/4885 |
| US-20040225150-A1 | Methods for selectively removing counterions from compounds and compounds derived from such methods | BHMT2, MGMT, BHMT | NOS1 3242/4885NOS2 2227/4885NOS3 2645/4885 |
| US-20020019563-A1 | Amidino compound and salts thereof useful as nitric oxide synthase inhibitors | NOS2, NOS1, NOS3 | NOS1 2/4885NOS2 1/4885NOS3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.